University of Groningen

Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia

Visser, J; Nijman, H W; Hoogenboom, B-N; Jager, P; van Baarle, D; Schuurin, E;
Abdulahad, W; Miedema, F; van der Zee, A G; Daemen, T

Published in:
Clinical and Experimental Immunology

DOI:
[10.1111/j.1365-2249.2007.03468.x](https://doi.org/10.1111/j.1365-2249.2007.03468.x)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2007

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Visser, J., Nijman, H. W., Hoogenboom, B-N., Jager, P., van Baarle, D., Schuurin, E., Abdulahad, W., Miedema, F., van der Zee, A. G., & Daemen, T. (2007). Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. *Clinical and Experimental Immunology*, 150(2), 199-209. <https://doi.org/10.1111/j.1365-2249.2007.03468.x>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia

J. Visser,^{*,†} H. W. Nijman,^{*}

B.-N. Hoogenboom,^{*,†} P. Jager,[†]

D. van Baarle,[‡] E. Schuurin,[§]

W. Abdulahad,[¶] F. Miedema,[‡]

A. G. van der Zee,^{*} and T. Daemen[†]

^{*}Department of Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, [†]Department of

Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, the

Netherlands, [‡]Department of Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, [§]Department of Pathology, University Medical Center Groningen, University

of Groningen, Groningen, the Netherlands, and [¶]Department of Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Accepted for publication 18 June 2007

Correspondence and current affiliation: Dr

J. T. J. Visser, University Medical Center

Groningen, University of Groningen,

Department of Cell Biology, Section

Immunology, 3215 11th Floor, A. Deusinglaan

1, 9713 AV, Groningen, the Netherlands.

E-mail: j.t.j.visser@med.umcg.nl

Summary

Oncogenic human papillomavirus (HPV)-infection is crucial for developing cervical cancer and its precursor lesions [cervical intraepithelial neoplasia (CIN)]. Regulatory T cells (T_{regs}) might be involved in the failure of the immune system to control the development of HPV-induced cancer. We investigated frequencies, phenotype and activity of T_{regs} in patients with cervical neoplasia. CIN and cervical cancer patients showed increased $CD4^{+}/CD25^{\text{high}}$ T cell frequencies in peripheral blood and $CD4^{+}$ T cell fraction. These $CD4^{+}/CD25^{\text{high}}$ T cells represent T_{regs} as demonstrated by their low proliferation rate, low interferon (IFN)- γ /interleukin (IL)-10 ratio, high expression of CD45RO, GITR, CTLA-4, forkhead box P3 (FoxP3) and low CD45RA expression. Moreover, in HPV16⁺ cervical cancer patients, *in-vitro* depletion of $CD25^{+}$ T cells resulted in increased IFN- γ T cell responses against HPV16 E6- and E7 peptides. Thus, increased frequencies of T_{regs} in cervical cancer patients may indeed suppress HPV-specific immunity. Longitudinal analysis of $CD4^{+}/CD25^{\text{high}}$ T cell frequencies in patients showed a modest decline 1 year after curative surgery or chemoradiation. This study demonstrates increased frequencies and suppressive activity of T_{regs} in cervical cancer. These results imply that T_{regs} may suppress the immune control of cervical neoplasia and furthermore that suppression of immunity by T_{regs} will be another hurdle to overcome in therapeutic immunization strategies against cervical neoplasia.

Keywords: $CD4^{+}$ T cell, $CD8^{+}$ T cell, cervical cancer, HPV, regulatory T cells

Introduction

Natural regulatory T cells (T_{regs}), characterized by co-expression of CD4 and CD25, play an important role in immune homeostasis [1–4]. In animal tumour models, elevated frequencies of T_{regs} have been demonstrated and T_{reg} depletion increased the anti-tumour immune responses [5,6]. These observations led to the hypothesis that cancer patients have an enlarged population of T_{regs} inhibiting tumour-specific T cell responses [1–3]. A recent study showed that $CD4^{+}/CD25^{+}$ T_{regs} control the induction of antigen-specific T-helper responses in cancer patients [7]. Intratumoral T_{regs} have been demonstrated in ovarian cancer patients [8] and an enlarged population of T_{regs} in peripheral blood of patients with different types of cancer [9–13].

Infection with oncogenic human papillomavirus (HPV) is involved in cervical carcinogenesis; HPV DNA can be detected in $\geq 99\%$ of all cervical cancers [14,15]. Most women infected with oncogenic HPV types clear the infection and do not develop (pre)malignant cervical neoplasia. The importance of the immune system in HPV clearance is demonstrated by observations that immunocompromised women fail more often to clear HPV infections and have an increased risk of developing cervical cancer [16].

The E6 and E7 oncoproteins of HPV play a crucial role in the transformation and maintenance of the malignant phenotype [15]. Several reports showed impaired cellular immunity against the HPV16 E6 and/or E7 oncoproteins in cervical cancer patients [17–20]. It has been suggested that impaired cellular immunity against these oncoproteins is responsible for the failure to eradicate HPV infections,

Table 1. Patient characteristics.

CIN patients					Cervical cancer patients				
Patient no.	Age (years)	Diagnosis	Grade	HPV16 status	Patient no.	Age (years)	Diagnosis	Stage	HPV16 status
1	26	CIN	I	neg	1	37	SCC	IA1	pos
2	28	CIN	I	neg	2	30	SCC	IA1	pos
3	27	CIN	I	neg	3	71	SCC	IB1	pos
4	50	CIN	I	?	4	36	SCC	IB1	pos
5	45	CIN	I	?	5	33	SCC	IB	neg
6	27	CIN	I	neg	6	40	SCC	IB1	neg
7	41	CIN	I	pos	7	75	SCC	IB1	pos
8	48	CIN	I	?	8	60	SCC	IB1	pos
9	34	CIN	II	pos	9	35	SCC	IB1	pos
10	34	CIN	III	neg	10	45	SCC	IB1	neg
11	33	CIN	III	pos	11	36	SCC	IB1	neg
12	45	CIN	III	pos	12	33	SCC	IB2	pos
13	40	CIN	III	?	13	26	SCC	IBII	pos
14	38	CIN	III	neg	14	54	SCC	IIA	pos
15	40	CIN	III	pos	15	43	SCC	IIB	pos
16	40	CIN	III	pos	16	70	SCC	IIB	neg
17	35	CIN	III	?	17	43	SCC	IIB	pos
18	30	CIN	III	?	18	46	SCC	IIB	pos
					19	36	SCC	IIB	pos
					20	48	SCC	IIB	pos
					21	51	SCC	IIB	pos
					22	41	SCC	IIB	pos
					23	45	SCC	IIB	neg
Avg 35 ± 8					Avg 45 ± 13				

CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; HPV, human papillomavirus.

leading subsequently to (pre)malignant cervical neoplasia [18]. In other studies, significant cellular immune responses against HPV16 E6 and/or E7 were demonstrated in cervical intraepithelial neoplasia (CIN) and cervical cancer patients [21–23]. However, these responses seem unable to clear HPV infections [21–23]. Interestingly, we observed that (suboptimal) T cell responses against HPV in CIN and cervical cancer patients can be enhanced by invasive surgical procedures [21].

CD4⁺/CD25⁺ T_{regs} have been found in tumour-draining lymph nodes of cervical cancer patients [24,25]. Immunohistochemistry also revealed the presence of CD25⁺ T_{regs} in infiltrate associated with CIN lesions [26]. However, in these studies frequencies and phenotypes of T_{regs} in CIN or cervical cancer patients were not compared to healthy controls; nor was suppression of (HPV-specific) cellular immune responses by T_{regs} determined.

To elucidate the role of T_{regs} in developing (pre)malignant cervical neoplasia, we evaluated frequencies, phenotype and suppressive activity of CD4⁺/CD25⁺ T cells in peripheral blood of patients with cervical cancer or CIN and healthy controls. Longitudinal analysis of T_{reg} frequencies was performed during and following therapy. We also investigated if the previously observed suboptimal T cell responses against HPV can be ascribed to increased frequencies/activities of T_{regs}.

Materials and methods

Ethical approval

The study was approved by the local medical ethical committee of the University Medical Center Groningen (UMCG). Written informed consent was obtained from all patients.

Patients

CIN and cervical cancer patients (Table 1) were recruited from the out-patient clinic of the gynecology department at the UMCG, as described previously [21]. In the Netherlands, cervical smears are classified according a modified Papanicolaou system in which borderline dyskaryosis corresponds well with the Bethesda classification of atypical squamous cells of undetermined significance, mild dyskaryosis with low-grade squamous intraepithelial lesions and moderate and severe dyskaryosis and carcinoma *in situ* with high-grade squamous intraepithelial lesions [27]. Patients referred with cervical carcinoma were staged according FigO criteria [28]. In general, patients with FigO stages Ib/IIa were treated by radical surgery and patients with stages IIB–IV were treated with chemoradiation. Radiotherapy consisted of 50 Gy in 25 fractions, five fractions a week, combined with

two fractions of brachytherapy if indicated. In addition to radiotherapy, patients received 40 mg/m² of cisplatin per week for 6 weeks.

Female healthy volunteers (age 39 ± 11 years) were recruited from the departments of gynecology and medical microbiology of the UMCG.

Isolation of cell subsets

Heparinized blood (50 ml) was obtained and peripheral blood mononuclear cells (PBMC) were isolated with a Ficoll-density gradient. PBMC were cryopreserved using standardized conditions enabling batchwise analysis at a later time.

Using fluorescent activated cell-sorting, thawed PBMC of healthy controls and patients with (pre)malignant cervical neoplasia were separated into CD4⁺/CD25^{neg} T cells, CD4⁺/CD25^{low} T cells and CD4⁺/CD25^{high} T cells. PBMC were stained with αCD4-APC (IQ Products, Groningen, the Netherlands) and αCD25-fluorescein isothiocyanate (FITC) antibodies (BD Biosciences, San Diego, CA, USA). Cells of interest were isolated with a Dako-Cytomation MoFlo High-Speed Sorter (Glostrup, Denmark), using gate-settings as described previously [13,29].

Flow cytometry

PBMC were stained with αCD25-FITC (BD Biosciences), αCD152-PE (CTLA4; BD Biosciences), anti-glucocorticoid-induced tumour necrosis factor (TNF) receptor family-related gene (GITR)-phycoerythrin (PE) (R&D Systems, Minneapolis, OK, USA), αCD45RO-PE (IQ Products), αCD4-antigen-presenting cell (APC) (IQ Products), anti-forkhead box P3 (FoxP3)-PE (eBioscience) and isotype controls to determine the immunophenotype of the different CD25 T cell subsets. Flow cytometry was performed and cells were measured with a fluorescence activated cell sorter (FACS) Calibur (BD Biosciences). Cells were analysed using CellQuest software (BD Biosciences).

Cell cultures, cytokine- and proliferation assays

Isolated CD4⁺/CD25 T cell subsets were cultured at a density of 2.5 × 10⁴ cells/well in 96-well round-bottomed plates (Nunc, Rochester, NY, USA). Cells were cultured in a volume of 200 µl RPMI-1640 (GIBCO, Breda, the Netherlands) supplemented with 10% fetal calf serum (FCS) (BioWhittaker, Verviers, Belgium), penicillin/streptomycin and 50 µM β-mercaptoethanol.

Cells were stimulated with 0.75 µg/ml αCD3/1 µg/ml αCD28 (Sanquin Research, Amsterdam, the Netherlands). Culture supernatants were harvested after 3 days and cell proliferation was measured by overnight [³H]-thymidine incorporation (1 µCi/well; Amersham, Bucks, UK). Labelled cells were harvested and [³H]-thymidine incorporation

measured with a liquid scintillation counter (Canberra-Packard, Meriden, CT, USA).

Cytokines were measured in culture supernatants using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Sanquin Research).

Expansion and detection of interferon (IFN)-γ-producing HPV16E6- and E7-specific T cells

For expansion and detection of HPV16 E6- and E7-specific T cells, we adapted an assay developed previously for detection of Epstein-Barr virus-specific CD4⁺ and CD8⁺ T cells [30,31]. HPV16 E6- or E7-specific T cells were stimulated using 15-mer peptides with an 11-aa overlap spanning the complete sequence of HPV16 E6 (37 peptides) or E7 (22 peptides) protein. Peptides were synthesized by Mimotopes/Perbio Sciences. Purity (> 90%) and sequences were verified by high performance liquid chromatography (HPLC)/mass-spectrometry. Peptides were dissolved in dimethylsulphoxide (DMSO) and pooled (final concentration of 1 mg/ml of each peptide). Stimulations with peptide pools and medium were performed in the presence of co-stimulation (2 µg/ml αCD28). As a negative control, cells were stimulated with medium and co-stimulation only. As a positive control, cells were stimulated with 10 ng/ml phorbol myristate acetate (PMA)/2 µg/ml ionomycin.

To expand HPV16 E6- or E7-specific T cells, total PBMC or CD25⁺ cell-depleted PBMC were cultured for 12 days in the presence of E6 or E7 peptide pools. Culture medium consisted of RPMI-1640 (GIBCO) supplemented with penicillin/streptomycin, 50 µM β-mercaptoethanol and 10% human pool serum (Sigma, Zwijndrecht, the Netherlands; complete medium). Cells were cultured at 2 × 10⁵ PBMC/well in 100 µl complete medium in 96-well round-bottomed plates at 37°C and 5% CO₂. The peptide pool (at 2 µg/ml of each peptide) was added on days 0 and 6. Interleukin (IL)-2 (10 U/ml) was added on days 3, 6 and 9. On day 12, cells were pooled, washed in RPMI-1640 and incubated overnight in complete medium.

On day 13, the number of IFN-producing cells were determined by intracellular cytokine staining; 10⁶ cells were stimulated in 500 µl complete medium for 6 h with HPV16 E6 or E7 peptide pools (at 2 µg/ml of each peptide) and αCD28 (2 µg/ml; Sanquin Research) as co-stimulation. After 1 h, brefeldin-A (Golgiplug; BD Biosciences) was added at a dilution of 1 : 1000 to allow cytokine accumulation in the cytosol. After stimulation, cells were washed in phosphate-buffered saline (PBS) + 0.5% bovine serum albumin (BSA), permeabilized (FACS permeabilizing solution; BD Biosciences), washed again and stained with αCD3-PE/Cy5 (Sanquin Research), αCD4-APC (IQ Products), αCD8-FITC (Sanquin Research) and anti-IFN-PE (IQ Products). Cells were washed again, fixed (Cellfix; BD Biosciences) and 2 × 10⁵ events were acquired on a FACSCalibur and data analysed using CellQuest software.

Enzyme-linked immunospot (ELISPOT) to determine HPV16 E6- and E7-specific T cell responses

Cryopreserved PBMC were thawed and CD25⁺ T cells were depleted using anti-CD25 Microbeads (Miltenyi-Biotec, Bergisch-Gladbach, Germany) according to the manufacturer's instructions. This procedure leads to complete removal of CD4⁺/CD25^{high} T cell fractions. Unseparated PBMC and CD25-depleted were seeded at a density of 1.5×10^6 cells/well in a 24-well plate (Corning Life-Sciences, Schiphol-Rijk, the Netherlands) in 1.5 ml complete medium in the presence or absence of HPV16 E6 or E7 peptide-pools (10 µg/ml of each peptide).

After 4 days of incubation, PBMC were harvested, washed and seeded in quadruplicate at a density of 1×10^5 cells/well in a coated ELISPOT-plate (Nunc, Silent-screen, Rochester, NY, USA) with an IFN-γ catching antibody (IFN-γ ELISPOT assay; Sanquin Research). The assay was performed further according to the manufacturer's instructions (Sanquin Research). ELISPOT plates were analysed with a fully automated imaging device (A.EL.VIS, Hanover, Germany). The background in medium control wells was below 10 spots/ 1×10^5 cells. Specific spots were calculated using criteria similar to other studies [17–19,21]. Specific responses were calculated by subtracting the mean number of spots ± 2 s.d. of medium control wells from the mean number of spots of experimental wells. Response against HPV16 E6 or E7 peptide-pools were considered positive when the number of specific spots was $\geq 10/1 \times 10^5$ cells and the response in the experimental wells was at least two times the background levels. As a positive control, PBMC were stimulated with a memory recall mix (MRM; kind gift of Dr S. van der Burg, LUMC, the Netherlands), consisting of a mixture of *Tetanus toxoid* (0.75 LF/ml), *Mycobacterium tuberculosis* sonicate (2.5 µg/ml) and *Candida albicans* (0.005%).

Establishing HPV16 status

HPV16 status was established by HPV16-specific polymerase chain reaction (PCR) on DNA isolated from cervical scrapings obtained at the patient's initial visit. The scraped cells were suspended in 5 ml PBS and kept on ice. The HPV16-specific PCR was performed as described previously [21]. HPV16-primers [product 152 base pairs (bp)] were: sense: TGCTAGTGCTTATGCAGCAGCAA, anti-sense: ATTTACTGCAACATTGGTAC.

Statistical analysis

Differences between groups were determined using the Mann-Whitney *U*-test and χ^2 test. Significance was determined as $P < 0.05$.

Results

Frequencies of CD4⁺/CD25⁺ T cells in peripheral blood of healthy controls, patients with CIN and cervical cancer

CD4⁺/CD25⁺ and CD4⁺/CD25^{high} T cells (Fig. 1a,d) were examined in patients with CIN, cervical cancer and healthy controls, using gate-settings as described previously [13,29]. As shown in Fig. 1, CD4⁺/CD25⁺ (Fig. 1b,c) and CD4⁺/CD25^{high} T cells (Fig. 1e,f) were significantly increased in both total PBMC (Fig. 1b,e) and CD4⁺ T cell fraction (Fig. 1c,f) of patients with CIN and cervical cancer compared to healthy controls.

Immune phenotype and FoxP3 expression of CD4⁺/CD25 T cell subsets

CD4⁺/CD25^{high} T cells of representative CIN patients, cervical cancer patients and healthy controls were characterized further for the expression of CD45RO, GITR, CTLA-4 and CD45RA. The three first molecules are expressed relatively highly and CD45RA is expressed relatively low on T_{regs} [1–3,9–13,29]. CD4⁺/CD25^{high} T cells of patients and controls expressed increased levels of CD45RO, CTLA-4 and GITR compared to CD4⁺/CD25^{neg} T cells (data not shown). Also, as the CD4⁺/CD25^{high} T cells expressed much lower CD45RA levels than CD4⁺/CD25^{neg} T cells (data not shown), the CD4⁺/CD25^{high} T cells of CIN and cervical cancer patients phenotypically resemble T_{regs}.

The transcription factor FoxP3 is considered to be a specific marker for T_{regs} [1,32,33]. Therefore, we analysed FoxP3 expression in the CD4⁺/CD25 T cell subsets (Fig. 2, upper panel). In both healthy controls and cervical cancer patients, the majority of CD4⁺/CD25^{high} T cells expressed FoxP3, while CD4⁺/CD25^{neg} T cells and CD4⁺/CD25^{low} T cells expressed FoxP3 at very low and moderate levels, respectively (Fig. 2, lower panel).

Cytokine profiles of CD4⁺/CD25^{neg} and CD4⁺/CD25^{high} T cell subsets

In general, T_{regs} are characterized by low proliferation, low IFN-γ production and robust IL-10 production [1–3,9–13,29]. CD4⁺/CD25^{neg} and CD4⁺/CD25^{high} T cells were isolated by cell-sorting (Fig. 3a) to study their functionality *in vitro*.

The CD4⁺/CD25^{high} subset showed a low proliferation rate (Fig. 3b), high levels of IL-10 production (Fig. 3c) and low IFN-γ production (Fig. 3d). The CD4⁺/CD25^{neg} subset, on the other hand, showed the opposite profile. Although CD4⁺/CD25^{high} and CD4⁺/CD25^{neg} cells of cervical cancer patients, on average, produced lower cytokine levels, the cytokine profile of these T cell subsets was similar compared to these subsets in healthy controls and patients with CIN.

Fig. 1. (a, d) Gate-settings for calculating CD4⁺/CD25⁺ and CD4⁺/CD25^{high} T cell frequencies. Markers to establish CD4⁺/CD25⁺ T cell frequencies are set on the isotype control. (b, c) CD4⁺/CD25⁺ T cell frequencies in total peripheral blood mononuclear cells (PBMC) (b) and CD4⁺ T cell population (c). (e, f) CD4⁺/CD25^{high} T cell frequencies in total PBMC and CD4⁺ T cell population, respectively. Analysis was performed with PBMC collected before invasive therapy. Differences between groups were analysed using the Mann–Whitney *U*-test.

Effect of CD25⁺ T cell depletion on HPV16 E6/E7-specific and general T cell responses

Using IFN- γ ELISPOT analysis, we determined the influence of CD4⁺/CD25⁺ T cells on HPV16 E6- and E7-specific T cell responses in patients with cervical cancer.

In vitro, depletion of CD25⁺ T cells enhanced IFN- γ T cell responses against HPV16 E6 and/or E7 peptide-pools in 50% (five of 10) of the HPV16-DNA⁺ cervical cancer patients (Table 2; $P = 0.05$ compared to HPV16^{neg} cervical cancer patients and $P = 0.07$ compared to the controls). In HPV16^{neg} cervical cancer patients no significant responses against HPV16 E6 and E7 peptide-pools were observed, and in only one healthy control CD25⁺ T cell depletion enhanced the HPV16 E6-specific T cell response (Table 2).

In a number of HPV16-DNA⁺, HPV16-DNA^{neg} and control donors, depletion of CD25⁺ T cells enhanced MRM-specific T cell responses (Table 2). In one patient (patient 7) and three controls (controls 3, 5, 10) depletion of CD25⁺ T cells caused a decrease of MRM-specific T cell responses. This is probably due to depletion of CD25⁺ activated memory T cells.

Using standard IFN- γ ELISPOT analysis the total T cell response is measured, not discriminating between CD4⁺ and CD8⁺ T cell responses. As T_{regs} control both CD4⁺ and CD8⁺ T cell responses [1–4], we determined if depletion of CD25⁺ T cells enhances HPV-specific T cell responses of both cell subsets.

All cervical cancer patients thus analysed displayed low, yet detectable CD4⁺ T cell responses against HPV16 E6 and/or E7 peptide-pools (Table 3). As observed by others [19–22], we also found higher CD4⁺ and CD8⁺ T cell responses against the E6 peptide pool compared to the E7 peptide pool (Table 3). Upon depletion of CD25⁺ cells, the response was enhanced in the CD4⁺ T cell fraction in three of four patients. Patients 2, 4 and 20 showed CD8 responses against the HPV16 E6 and/or E7 peptide pools. However, in only patient 2 was the E6-specific response enhanced after CD25⁺ cell depletion. Background IFN- γ production was not enhanced significantly by CD25⁺ cell depletion. Although the results for the HPV16 E6- and E7-specific CD8⁺ responses are inconclusive, these results suggest that CD25⁺ T cells can at least suppress the HPV16 E6- and/or E7-specific CD4⁺ T cell responses.

Fig. 2. Forkhead box P3 (FoxP3) expression was measured by flowcytometry in CD4⁺/CD25 subsets of a healthy control and three cervical cancer patients with peripheral blood mononuclear cells collected before invasive therapy. The upper panel shows gate-settings for CD4⁺/CD25^{neg}, CD4⁺/CD25^{low} and CD4⁺/CD25^{high} cells. Within the T cell fractions FoxP3 expression was analysed (lower panel).

Longitudinal follow-up of CD4⁺CD25^{high} T cell frequencies in patients with cervical cancer

Longitudinal analyses of CD4⁺/CD25^{high} T cell frequencies were performed in four healthy controls and 10 cervical cancer patients during and following therapy. In healthy controls the CD4⁺/CD25^{high} T cell population appeared very stable (Fig. 4a). In two patients with cervical cancer who underwent curative surgery only, with no sign of recurrence for more than 2 years, CD4⁺/CD25^{high} T cell frequencies showed a modest decline following curative surgery (Fig. 4b,c). CD4⁺/CD25^{high} T cell frequencies showed strong fluctuation in patients treated with chemoradiation (RCT; Fig. 4d–k). In six patients the CD4⁺/CD25^{high} T cell

frequencies increased after radiochemotherapy (Figs 4d–h, k); in two patients these frequencies remained stable (Fig. 4i,j). After completion of chemoradiation, CD4⁺/CD25^{high} T cell frequencies did not fall below the levels as measured before chemoradiation in all eight patients.

Discussion

In this study we provide evidence that patients with CIN and cervical cancer have increased CD4⁺/CD25^{high} T_{reg} frequencies in their peripheral blood compared to healthy controls. Our data show that these CD4⁺/CD25^{high} T cells, but not CD4⁺/CD25^{low} T cells, of CIN and cervical cancer patients display all T_{reg} characteristics. The CD4⁺/CD25^{high} T cells

Fig. 3. (a) Gate-settings used for sorting the different CD4⁺/CD25 T cell populations. White bars represent the CD25^{neg} T cells and the black bars the CD25^{high} T cells. Cell-sorting experiments were performed with peripheral blood mononuclear cells (PBMC) collected before invasive therapy of seven representative controls, 11 representative patients with cervical intraepithelial neoplasia and 12 representative patients with cervical cancer. Proliferation (b) is expressed as dissociations per second (dps; mean $\pm$ s.e.m.), interleukin-10 (c) and interferon- γ (d) production as pg/ml (mean $\pm$ s.e.m.).

express high levels of CD45RO, GITR and CTLA-4. Furthermore, these CD4⁺/CD25^{high} T cells produce high levels of IL-10, low levels of IFN- γ and have a low rate of proliferation. Moreover, this subset is highly positive for the T_{reg}-specific marker FoxP3.

It has been shown that *in vitro* CD25⁺ T cell depletion enhanced virus-specific CD4⁺ and/or CD8⁺ T cell responses [33]. Moreover, in melanoma patients, CD4⁺/CD25⁺ T_{regs} control tumour-specific CD4⁺ T cell responses [7]. We therefore hypothesized that increased T_{reg} numbers in cervical cancer patients might be responsible for impaired cellular immunity against HPV. Indeed, *in vitro* depletion of CD25⁺ T cells, enhanced HPV16 E6- and/or E7-specific T cell responses in 50% of the HPV16-DNA^{pos} cervical cancer patients. This enhancement did not occur in HPV16-DNA^{neg} cervical cancer patients, while only one healthy control showed an enhanced E6-specific T cell response, probably reflecting T cell memory of previous HPV-infection(s). Our results indicate that suppression of HPV16 E6/E7-specific T cell responses by CD25⁺ cells was at the level of CD4⁺ and possibly also CD8⁺ T cells. The increased IFN- γ responses

could not be explained by enrichment of responder T cells after CD25⁺ cell depletion, because relative changes of CD4⁺ T and CD8⁺ T cells remained below 4% and 2%, respectively (data not shown).

CD25⁺ T cell depletion also enhanced T cell responses against MRM in a considerable number of cervical cancer patients and healthy controls. In one patient (patient 7) and three controls (controls 3, 5 and 10), CD25⁺ T cell depletion resulted in a decrease of the MRM-specific T cell response. In view of the fact that activated memory T cells express increased levels of CD25, this decrease might be due to depletion of activated memory T cells.

The simultaneous increase of HPV16 and MRM-specific T cell responses in HPV16⁺ cervical cancer patients after CD25⁺ T cell depletion indicate that suppression of cell-mediated immunity by T_{regs} in these patients is not antigen-specific. However, our results imply that increased frequencies of T_{regs} in cervical cancer patients might suppress the immunological control of cervical neoplasia. Insufficient cell numbers were available to characterize further the suppression of general immune responses by T_{regs} in cervical cancer patients.

Table 2. Effect of CD25⁺ cell depletion on interferon (IFN)- γ T cell responses against HPV16 E6 and/or E7 in cervical cancer patients and healthy controls.

Cervical cancer patients	PBMC			CD 25 depleted PBMC		
	E6	E7	MRM	E6	E7	MRM
HPV16 pos						
Patient 1	9	3	38	9	10	88
Patient 2	0	0	31	0	9	37
Patient 3	0	1	> 400	0	6	> 400
Patient 7	0	0	170	0	0	91
Patient 8	3	2	12	42	16	74
Patient 12	12	4	39	43	29	56
Patient 14	1	3	38	7	10	76
Patient 15	0	0	45	2	0	56
Patient 19	0	1	39	4	3	157
Patient 21	7	3	> 400	14	7	> 400
HPV16 neg						
Patient 5	0	0	> 400	0	0	> 400
Patient 6	0	1	6	0	4	95
Patient 10	0	0	0	9	0	4
Patient 11	0	0	102	0	0	167
Patient 16	1	1	28	0	1	38
Controls						
Control 1	0	1	77	0	0	112
Control 2	1	1	65	0	3	80
Control 3	0	1	170	0	2	51
Control 4	0	0	5	0	0	85
Control 5	0	0	170	0	0	120
Control 6	0	1	43	0	0	118
Control 7	0	10	110	0	0	159
Control 8	0	2	49	X	X	X
Control 9	0	0	78	21	0	79
Control 10	0	0	> 400	6	0	269

HPV16 E6- and E7-specific T cell responses in patients with cervical cancer and controls as determined by interferon (IFN)- γ enzyme-linked immunospot. The table shows the number of spots per 1×10^5 cells. Shown are the responses in total peripheral blood mononuclear cells (PBMC) and the CD25-depleted PBMC. Specific responses ($\geq 10/1 \times 10^5$ cells) are indicated in bold type. Analyses were performed with PBMC collected before invasive therapy. MRM: memory recall mix, E6: E6 peptide pool, E7: E7 peptide pool, X: insufficient cells available for analysis.

Table 3. Effect of CD25⁺ cell depletion on antigen-specific interferon (IFN)- γ responses against human papilloma virus (HPV)16 E6 and/or E7 in both CD4⁺ and CD8⁺ T cell subsets of HPV16⁺ cervical cancer patients.

Cervical cancer patients	PBMC			CD25 depleted PBMC		
	Neg control	E6 pept	E7 pept	Neg control	E6 pept	E7 pept
% IFN- γ + CD4 ⁺ T cells						
Patient 2	0.9	3.4	3.6	1	7.5	4.8
Patient 4	2.3	7	2.9	2.8	9.2	n.a.
Patient 20	0.4	2.3	0.6	0.4	4.5	1.6
Patient 22	0.8	7.1	1.7	1.2	7.8	1.4
%IFN- γ + CD8 ⁺ T cells						
Patient 2	0.5	1.4	0.8	0.3	6.3	0.8
Patient 4	0.8	4.1	1.9	n.a.	n.a.	n.a.
Patient 20	0.4	2.1	0.6	0.7	1.7	1
Patient 22	0.5	0.7	0.3	0.3	0.6	0.3

Human papilloma virus (HPV)16 E6 and E7-specific interferon (IFN)- γ T cell production was measured by intracellular cytokine staining after *in vitro* expansion for 12 days with peripheral blood mononuclear cells (PBMC) or CD25-depleted PBMC of four HPV16⁺ cervical cancer patients in the presence of HPV16 E6 or E7 peptide pools. The results are expressed as percentage IFN- γ positive cells within the CD4⁺ or CD8⁺ T cell fraction. Positive responses (at least two times the background) are indicated in bold type. Analyses were performed with PBMC obtained before invasive therapy. E6 pept: E6 peptide pool, E7 pept: E7 peptide pool, n.a. insufficient cells available for analysis.

Fig. 4. The figure shows the longitudinal CD4⁺/CD25^{high} T cell frequencies as a percentage of the CD4⁺ T cell fraction in four healthy controls (a) and 10 cervical cancer patients (c–k) during and following their therapy. Type of intervention/therapy and remarks about clinical status is mentioned in the figure. EUA: examination under anaesthesia; RCT: radiotherapy combined with chemotherapy.

Our results regarding suppression of HPV16 E6- and E7-specific T cell responses by CD25⁺ T cells shed new light on observations of relatively low or impaired HPV-specific cellular immunity in cervical cancer patients [17–23]. In this study we provide evidence that intrinsically these anti-HPV responses exist, but are suppressed by T_{regs}. Therefore, the observed (low) level of HPV-specific immunity in PBMC of cervical cancer patients [17–23] is most probably an under-estimation of the actual HPV-specific T cell numbers.

Malignant cervical tumour cells can produce large amounts of transforming growth factor (TGF)- β [34]. Because TGF- β induces T_{reg} development [35], this might be one of the mechanisms leading to increased T_{reg} levels in

cervical cancer patients. However, theoretically, it cannot be ruled out that women developing CIN or cervical cancer display intrinsically increased T_{reg} numbers. If the increased T_{reg} numbers are induced by the cervical tumour only, tumour eradication might lead to a decline in T_{reg} numbers. However, we found only a modest decline of CD4⁺/CD25^{high} T cell frequencies in the year following curative surgery. Patients treated with chemoradiation showed strong fluctuations but no decrease of their CD4⁺/CD25^{high} T cell frequencies during and following therapy. Chemoradiation causes tissue damage and apoptosis which may lead to immune activation. As a consequence the number of T_{regs} might be up-regulated to prevent immune pathology [1–4]. It remains

an unanswered question as to whether T_{regs} are induced or already present in patients with (pre)malignant cervical neoplasia. Therefore, further research will be required to elucidate fully the influence of therapy on T_{regs} in these patients.

Because E6 and E7 transforming oncoproteins are crucial for transformation and maintenance of the malignant phenotype, they are ideal candidates for tumour-specific cervical cancer immunotherapy [36]. The results presented in this study indicate that the presence of increased T_{reg} numbers is another hurdle to overcome for successful therapeutic immunotherapy, especially when this therapy is given as an adjuvant to chemoradiation. Therefore, immunization strategies should elicit strong anti-tumour immune responses: strong enough to overcome the immunosuppressive state of the patient. Such strong responses have been described for immunizations with a genetic vector derived from Semliki-Forest virus (an alphavirus) expressing HPV16 E6/E7, which could break immune tolerance in HPV-transgenic mice [37].

Another approach could be (temporarily) bypassing suppression of cellular immunity by T_{regs} during therapeutic immunizations for treatment of (pre)malignant cervical neoplasia. The clinical potential of enhancing anti-tumour immune responses by T_{reg} depletion has been shown recently in patients with metastatic renal carcinoma [38]. However, interfering in T_{reg}-controlled immune responses should be conducted with extreme caution, because of the risk of developing autoimmunity [39].

Acknowledgements

We thank Nening Nanlohy, Klaske 10 Hoor, Harry Klip and Esther Nijhuis for their excellent assistance. T. Daemen, A. G. van der Zee and F. Miedema were supported financially by the Dutch Cancer Society, grant no. RUG 2001–2398; H. W. Nijman was supported financially by the Dutch Cancer Society, grant no. 2002–2678. J. Visser was supported financially by a grant from Maurits en Anna de Kock stichting.

References

- 1 Sakaguchi S. Naturally arising Foxp3-expressing CD25⁺ CD4⁺ regulatory T cells in immunological tolerance to self and non-self. *Nat Immunol* 2005; **4**:345–52.
- 2 von Boehmer H. Mechanisms of suppression by suppressor T cells. *Nat Immunol* 2005; **4**:338–44.
- 3 McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. *J Allergy Clin Immunol* 2002; **110**:693–702.
- 4 Mills KH. Regulatory T cells: friend or foe in immunity to infection? *Nat Rev Immunol* 2005; **4**:841–55.
- 5 Casares N, Arribillaga L, Sarobe P *et al.* CD4⁺/CD25⁺ regulatory T cells inhibit activation of tumor primed CD4⁺ T cells with IFN- γ -dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. *J Immunol* 2003; **171**:5931–9.
- 6 Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25⁺ CD4⁺ T cells: a common basis between tumor immunity and autoimmunity. *J Immunol* 1999; **163**:5211–8.
- 7 Nishikawa H, Jager E, Ritter G, Old LJ. CD4⁺ CD25⁺ regulatory T cells control the induction of antigen-specific CD4⁺ helper T cell responses in cancer patients. *Blood* 2005; **106**:1008–11.
- 8 Curiel TJ, Coukos G, Zou L *et al.* Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 2004; **10**:942–9.
- 9 Woo EY, Chu CS, Goletz TJ *et al.* Regulatory CD4⁺ CD25⁺ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res* 2001; **61**:4766–72.
- 10 Liyanage UK, Moore TT, Joo HG *et al.* Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. *J Immunol* 2002; **169**:2756–61.
- 11 Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. *Clin Cancer Res* 2003; **9**:606–12.
- 12 Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. *Clin Cancer Res* 2003; **9**:4404–8.
- 13 Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. *Cancer Res* 2005; **65**:2457–64.
- 14 Walboomers JM, Jacobs MV, Manos MM *et al.* Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; **189**:12–9.
- 15 Shah KV, Howley PM. Papillomaviruses. In: Fields BN, Knipe DM, Howley PM, eds. *Fields virology*. Philadelphia: Lippincott-Raven Publishers, 1995:2077–110.
- 16 Bouwes Bavinck JN, Berkhout RJ. HPV-infections and immunosuppression. *Clin Dermatol* 1997; **5**:427–37.
- 17 van Poelgeest MI, Nijhuis ER, Kwappenberg KM *et al.* Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. *Int J Cancer* 2006; **118**:675–83.
- 18 de Jong A, van Poelgeest MI, van der Hulst JM *et al.* Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4⁺ T-cell immunity against early antigens E2 and E6. *Cancer Res* 2004; **64**:5449–55.
- 19 Welters MJ, de Jong A, van den Eeden SJ *et al.* Frequent display of human papillomavirus type 16, E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. *Cancer Res* 2003; **63**:636–41.
- 20 Youde SJ, Dunbar PR, Evans EM *et al.* Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16, E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. *Cancer Res* 2000; **60**:365–71.
- 21 Visser J, van Baarle D, Hoozeboom BN *et al.* Enhancement of human papilloma virus type 16, E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. *Int J Cancer* 2006; **118**:2529–37.
- 22 Steele JC, Mann CH, Rookes S *et al.* T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. *Br J Cancer* 2005; **93**:248–59.
- 23 Luxton JC, Nath R, Derias N, Herbert A, Shepherd PS. Human

- papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. *J Gen Virol* 2003; **84**:1063–70.
- 24 Fattorossi A, Battaglia A, Ferrandina G *et al.* Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. *Gynecol Oncol* 2004; **92**:106–15.
 - 25 Fattorossi A, Battaglia A, Ferrandina G *et al.* Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. *Cancer* 2004; **100**:1418–28.
 - 26 Kobayashi A, Greenblatt RM, Anastos K *et al.* Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. *Cancer Res* 2004; **64**:6766–74.
 - 27 Bulkman NW, Rozendaal L, Snijders PJ *et al.* POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. *Int J Cancer* 2004; **110**:94–101.
 - 28 Finan MA, DeCesare S, Fiorica JV *et al.* Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival? *Gynecol Oncol* 1996; **62**:139–47.
 - 29 Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25^{high} regulatory cells in human peripheral blood. *J Immunol* 2001; **167**:1245–53.
 - 30 Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. *Blood* 2005; **106**:3166–74.
 - 31 Roncador G, Brown PJ, Maestre L *et al.* Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. *Eur J Immunol* 2005; **35**:1681–91.
 - 32 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; **299**:1057–61.
 - 33 Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. *J Virol* 2004; **78**:2454–9.
 - 34 Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. *J Immunol* 2001; **167**:2972–8.
 - 35 Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF- β . *J Immunol* 2005; **174**:1446–55.
 - 36 Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. *Nat Rev Immunol* 2004; **4**:46–54.
 - 37 Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. *Gene Ther* 2005; **12**:1410–4.
 - 38 Dannull J, Su Z, Rizzieri D *et al.* Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. *J Clin Invest* 2005; **115**:3623–33.
 - 39 Wei WZ, Jacob JB, Zielinski JF *et al.* Concurrent induction of anti-tumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. *Cancer Res* 2005; **65**:8471–8.